Welcome to the Inaugural Genetic Vaccine Development for Infectious Diseases Summit

The COVID-19 pandemic brought life-changing disruptions to people around the world and has turned the typical vaccine R&D process on its head. A combination of urgent need, unprecedented investments, and advances in genetic engineering has allowed what was once mere speculation to become not only our reality, but our future. With pandemic vaccines now launching at record speeds, the first Genetic Vaccine Development for Infectious Diseases Summit will focus on overcoming the translational and clinical challenges of developing genetic vaccines targeting infectious diseases, including Influenza, Lassa fever, Ebola, MERS, HIV, Zika, and COVID-19.

With a focus on mRNA, DNA, and engineered viral vector-based vaccines, this niche 3-day agenda has been specifically designed to help industry experts to:

Untitled design (40)

Progress your own expertise and experience while forging complementary partnerships and alliances

Untitled design (40)

Overcome immunogenicity challenges and design safe and efficacious vaccine formulations

Untitled design (40)

Define clinically meaningful endpoints to successfully develop and safely deliver optimal doses for public use

The digital Genetic Vaccine Development for Infectious Diseases Summit is not only the first, but the only dedicated meeting that brings you the most up to date clinical and commercial developments utilizing next-generation vaccine technologies for infectious diseases.  

Join 100+ experts online from companies such as BioNTech, Pfizer, Moderna, AstraZeneca, CureVac and more to discuss new genetic-based vaccine platforms, preclinical and clinical case studies, optimized delivery methods, and the future of vaccine R&D to usher in a new era of vaccinology.

29 World-Class Speakers, Including:

Andreas Kuhn, PhD

Sr. VP, RNA Biochemistry & Manufacturing

BioNTech

Johan Vekemans, PhD

Global Clinical Head, SARS-CoV-2 Vaccine

AstraZeneca

Lidia Oostvogels, PhD

VP Area Head Infectious Diseases

CureVac

Jacqueline Miller, MD

Sr. VP Therapeutic Area Head, Infectious Diseases

Moderna

Dan Barouch , PhD., MD.,

William Bosworth Castle Professor of Medicine

Harvard Medical School

Kate Broderick, PhD

Sr. VP, R&D

Inovio

Louis Picker, PhD

Associate Director & Professor

Vaccine and Gene Therapy Institute, OHSU

Philip Dormitzer, PhD

Vice President & Chief Scientific Officer: Viral Vaccines

Pfizer

Hildegund Ertl, PhD

Professor

The WISTAR Institute

Jason DeHart, PhD

Senior Principal Scientist, RNA & Targeted Therapeutics

Janssen

Norman Begg, PhD

Former Chief Medical Officer

GSK Vaccines

Ronit Satchi-Fainaro, PhD

Head, Cancer Research and Nanomedicine Laboratory

Tel Aviv University

What Do Our Speakers Have To Say?

"The vaccine landscape has been revolutionised by the advent of genetic vaccines. I am delighted to participate in this summit, to better understand how these powerful new tools can contribute to global public health"

- Norman Begg, Chief Medical Officer Emeritus, GSK Vaccines

 

"It was so well organized that it almost felt like you were there in person, and the sessions moved flawlessly" 

- Cerevel Therapeutics from the Gene Therapy Series